Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | SDHB | P21912 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554702 | 0.89 | MAPK9 (0.43) | MAPK9DYRK1ADYRK2DYRK1BMAPK8 | |
| SCHEMBL3549513 | 0.82 | DYRK1A (0.46) | DRD1MAPK9DYRK1ADYRK2DYRK1B | |
| SCHEMBL3557012 | 0.76 | CAMK2D (0.47) | DRD1MAPK9DYRK1AMAPK8FLT3 | |
| SCHEMBL3548686 | 0.73 | DYRK1A (0.62) | MAPK9DYRK1ADYRK2DYRK1BMAPK8 | |
| SCHEMBL14561140 | 0.73 | BRAF (0.46) | SDHBMAPK8FLT3EGFRKCNH2 | |
| SCHEMBL20294300 | 0.72 | DRD1 (0.45) | DRD1MKNK1 | |
| SCHEMBL20294474 | 0.70 | ALDH1A1 (0.52) | DRD1MKNK1 | |
| SCHEMBL1880365 | 0.70 | NPSR1 (0.44) | DRD1MKNK1 | |
| SCHEMBL27927010 | 0.69 | DYRK1A (0.41) | MAPK9DYRK1ADYRK2DYRK1BMAPK8 | |
| SCHEMBL12272611 | 0.69 | DYRK1A (0.38) | MAPK9DYRK1ADYRK2DYRK1BMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | DRD1 3018/4885MAPK9 156/4885DYRK1A 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.